Objectives To study the effects of XUEZHIKANG on lipid modulating and the level of oxidized low density lipoprotein(OX - LDL), C -reactive protein(CRP), fibrinogen(FIB) in serum. Methods XUEZHIKANG was given to patien...Objectives To study the effects of XUEZHIKANG on lipid modulating and the level of oxidized low density lipoprotein(OX - LDL), C -reactive protein(CRP), fibrinogen(FIB) in serum. Methods XUEZHIKANG was given to patients with unstable angina pectoris and hyperlipidemia at a dose of 0. 6 gram bid for 2 months and with half -dose for another 2 months. Vitamin E was given to unstable angina pectoris patients with normal lipid at the dose of 0. 1 gram bid for 4 months respectively. Then compared the level of lipid and OX - LDfL, CRP, FIB in serum at beginning, first - month and second -month. Results XUEZHIKANG can reduce the serum level of total cholesterol, low density lipoprotein in 1 month , and gained better effect in 2 months. It can also reduce triglyceride and increase high density lipoprotein in 2 months. Compared with vitamin E XUEZHIKANG can reduce the level of OX - LDL, CRP, FIB significantly after treatment for 2 months. Conclusions XUEZHIKANG has significant effect in lipid modulating , and it can also inhibit the development of inflammation in coronary plaque.展开更多
文摘目的探讨氧化应激及炎性反应指标在缺血性脑卒中的临床意义。方法检测缺血性脑卒中(ischemic stroke,IS)患者和健康对照组血清中总抗氧化能力(total antioxidant capacity,TAC)、氧化型低密度脂蛋白(oxidized low density lipoprotein,Ox-LDL)、超氧化物歧化酶(super oxide dismutase,SOD)、超敏C反应蛋白(high sensitivity C reactive protein,Hs-CRP)等指标的表达,采用ELISA方法检测血清TAC、Ox-LDL;在贝克曼库尔特AU5821全自动生化分析仪上检测其他指标的水平。结果 (1)治疗组较正常对照组血清中TAC显著性降低,几乎为健康人水平的1/12(P<0.01),高密度脂蛋白胆固醇(high density lipoprotein cholesterol,HDL-C)、SOD的水平有所下降(P<0.05);(2)Hs-CRP、Ox-LDL、低密度脂蛋白胆固醇(low density lipoprotein cholesterol,LDL-C)的水平显著性升高(均P<0.01),治疗组血清中Hs-CRP约为对照组的16倍,其OX-LDL水平约为1.7倍,LDL-C约为1.6倍。治疗组较对照组血清中氧化应激及炎性反应指标的表达差异有统计学意义。结论脑卒中的发生可能与氧化应激、炎性反应有重大关系。
文摘Objectives To study the effects of XUEZHIKANG on lipid modulating and the level of oxidized low density lipoprotein(OX - LDL), C -reactive protein(CRP), fibrinogen(FIB) in serum. Methods XUEZHIKANG was given to patients with unstable angina pectoris and hyperlipidemia at a dose of 0. 6 gram bid for 2 months and with half -dose for another 2 months. Vitamin E was given to unstable angina pectoris patients with normal lipid at the dose of 0. 1 gram bid for 4 months respectively. Then compared the level of lipid and OX - LDfL, CRP, FIB in serum at beginning, first - month and second -month. Results XUEZHIKANG can reduce the serum level of total cholesterol, low density lipoprotein in 1 month , and gained better effect in 2 months. It can also reduce triglyceride and increase high density lipoprotein in 2 months. Compared with vitamin E XUEZHIKANG can reduce the level of OX - LDL, CRP, FIB significantly after treatment for 2 months. Conclusions XUEZHIKANG has significant effect in lipid modulating , and it can also inhibit the development of inflammation in coronary plaque.